trending Market Intelligence /marketintelligence/en/news-insights/trending/LY1vZLVvtWUtDjEpixhvOA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

NattoPharma Q3 loss widens 35.9% YOY

Blog

COVID-19 Impact & Recovery: LCD Outlook for H2 2021

Blog

COVID 19 Impact Recovery Media Telecom and Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Technology Outlook for H2 2021

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


NattoPharma Q3 loss widens 35.9% YOY

NattoPharma ASA said its third-quarter normalized net income came to a loss of 30 Norwegian øre per share, compared with the S&P Capital IQ consensus estimate of a loss of 35 øre per share.

The per-share loss narrowed 22.0% year over year from 38 øre.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of 5.2 million kroner, compared with a loss of 3.8 million kroner in the prior-year period.

The normalized profit margin declined to negative 84.7% from negative 74.5% in the year-earlier period.

Total revenue increased 20.1% year over year to 6.2 million kroner from 5.1 million kroner, and total operating expenses grew 49.8% year over year to 17.3 million kroner from 11.6 million kroner.

Reported net income came to a loss of 8.1 million kroner, or a loss of 47 øre per share, compared to a loss of 6.0 million kroner, or a loss of 60 øre per share, in the year-earlier period.

As of Nov. 25, US$1 was equivalent to 8.66 Norwegian kroner.